

### IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
01167	Jacobio-B	2020/12/14	2020/12/18	2020/12/21

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit [www.cfsg.com.hk](http://www.cfsg.com.hk) or contact our account executives or customer service officers

### Subscription Details via CASH Securities

Offer Period	2020/12/09-2020/12/14
Closing Time for Margin Application	N/A
Subscription Fee	N/A
Indicative Interest Rate	N/A
Days For Margin Financing	N/A

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

### Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)

#### Share Offer Highlights

Total Number of Offer Shares:	96,476,100 Shares (subject to the Overallotment Option)
- Number of Public Offer Shares:	9,648,000 Shares (subject to reallocation)
- Number of Placing Shares:	86,828,100 Shares (subject to reallocation and the Over-allotment Option)
Number of Shares per Lot:	300 Shares
Offer Price:	HKD 12.00- 14.00 per Share
2019 Historical P/E ratio:	-
Sponsor:	Goldman Sachs, CICC

#### Company Overview

The Company is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of innovative oncology therapies. Established in July 2015, it is an explorer in developing clinical-stage small-molecule drug candidates to modulate enzymes by binding to their allosteric sites, i.e., sites other than the active site that catalyzes the chemical reaction, in order to address targets which are lack of easy-to-drug pockets where drugs can bind, such as protein tyrosine phosphatases (PTPs) and Kirsten rat sarcoma 2 viral oncogene homolog (KRAS). It intends to proactively explore and enter into strategic and synergistic partnerships with leading multinational corporations (MNCs), as exemplified by the collaboration with AbbVie for our innovative, allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors. Such partnerships pool complementary expertise and resources to increase the chances of success for its drug candidates and ensure maximization of their clinical and commercial value on a global scale..

For the year ended December 31, 2018 and 2019 and the six months ended June 30, 2020, the Company's net losses were RMB149.21 mn, RMB424.81 mn and RMB810.90 mn respectively.

#### Source

IPO Prospectus

#### Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpu Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026

**Declaration:**

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.